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Non-small Cell Lung Cancer Who Have Poor Performance
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Background: Patients with poor performance status and/or are
elderly are frequently considered a compromised group at high risk
of chemotherapy-related morbidities and less likely to benefit from
treatment. We aimed to evaluate tolerability and efficacy of three
single-agent regimens in these patients.
Patients and Methods: Patients with advanced non-small cell lung
cancer who had performance status 2/3 and/or were aged 70 and
older were randomly assigned to receive gemcitabine, vinorelbine,
or docetaxel. Objective response, toxicities, and quality of life were
evaluated.
Results: One hundred thirty-five patients were registered, of whom
one was ineligible. Of the 134 patients, 43 received gemcitabine, 45
vinorelbine, and 46 docetaxel. The response rate was 16%, 20%,
22% for gemcitabine, vinorelbine, and docetaxel, respectively. The
main grade 3/4 toxicities were fatigue (18%) and neutropenia (16%).
There was improvement in global health scores, cough, and dyspnea
for all treatment groups. The improvement in dyspnea was most
marked in patients with performance status 3.
Conclusion: There was no significant advantage of any of the
treatment arms over the rest. There was benefit seen with improve-
ment of quality of life in patients who were able to receive more
cycles of chemotherapy.
(J Thorac Oncol. 2007;2: 230–236)
In the early 1990s, meta-analysis of advanced non-small celllung cancer (NSCLC) patients showed a survival benefit for
patients who received cisplatin-based chemotherapy versus
those who had best supportive care alone.1–3 Palliative che-
motherapy has since become standard of care in patients who
are fit and generally consisted of a two-drug chemotherapy
schedule.4 Although this modest survival benefit has per-
suaded many to offer chemotherapy to patients with good
performance status (PS), most oncologists are still cautious
about administering such treatment to patients with poor PS
or who are elderly.
Although clinical response and improved survival are
still deemed important, it is now increasingly recognized that
palliation of symptoms and maintaining/improving quality of
life (QoL) are essential, if not more important, endpoints in
any palliative treatment. An important randomized study in
elderly NSCLC patients done by the Elderly Lung Cancer
Vinorelbine Italian Study Group demonstrated superior sur-
vival and QoL benefit in patients treated with single-agent
vinorelbine (VIN) over best supportive care alone.5 This
study has set the stage for many prospective studies as well as
retrospective analysis of chemotherapy in elderly NSCLC
patients.6–10
Along with a gradual acceptance of more aggressive
treatment for the elderly NSCLC patients, the mind-set to-
ward poor PS patients is also slowly changing. PS is fre-
quently a reflection of tumor burden and comorbidities and
has been shown to be an independent prognostic factor for
survival in advanced NSCLC patients.11,12 However, al-
though data on chemotherapy for PS 2 (based on Eastern
Cooperative Oncology Group [ECOG] scale) patients are
slowly emerging, few would venture to treat anyone with PS 3.
The aim of this study was to assess the tolerability,
objective response rate, and the impact on QoL using three
single-agent chemotherapy regimens for the treatment of poor
PS (ECOG 2 and 3) and/or elderly (70 years or older) patients
with advanced NSCLC in the context of a randomized phase
II trial and to determine whether any one arm is sufficiently
superior to warrant further study. The three chemotherapeutic
agents: gemcitabine (GEM), VIN, and docetaxel (DOC) were
chosen based on phase II studies that had shown tolerability
and efficacy in the treatment of elderly NSCLC patients.5,7,8
Secondary objectives were to assess progression-free survival
and overall survival.
*Department of Medical Oncology, National Cancer Centre; †Clinical Trials
and Epidemiology Research Unit; and ‡Department of Diagnostic Radi-
ology, National Cancer Centre, Singapore.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Swan Swan Leong, MD, Department of Med-
ical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore
169610. E-mail: dmolss@nccs.com.sg
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0203-0230
Journal of Thoracic Oncology • Volume 2, Number 3, March 2007230
PATIENTS AND METHODS
Eligibility Criteria
Patients with histologically proven stage IV or III
NSCLC (not amenable to curative treatment) who were
chemotherapy naive were eligible for the study, provided
they had a PS of ECOG 2 or 3 and/or were 70 years old or
older. There must be radiographically measurable disease and
adequate bone marrow, renal, and hepatic function. Patients
with previously treated brain metastasis were allowed to
participate. The Institutional Review Board approved the
study, and all patients provided written informed consent.
Pretreatment Evaluation
This consisted of a detailed history and physical exam-
ination, including documentation of PS. Complete blood cell
counts, renal function, and liver function panels were done.
Tumor staging was done using computed tomography (CT)
of the chest and upper abdomen within 30 days before
randomization.
Study Design
This was a prospective, randomized phase II trial.
Randomization was done through the central randomization
office of the Clinical Trials and Epidemiology Research Unit,
using a computer-driven minimization procedure. Stratifica-
tion factors were age (younger than 70 versus 70 or older) and
PS (0/1 versus 2/3).
The sample size calculation was based on the statistical
selection theory by Simon et al.13 To allow a 90% probability
of correctly selecting the most promising of the three treat-
ments for possible further studies, assuming a 15% superior-
ity of the best treatment over the others, a sample size of 45
patients per treatment group would be required, giving a total
accrual target of 135 patients.
Treatment
Patients were randomized to receive GEM 800 mg/m2,
VIN 25 mg/m2, or DOC 30 mg/m2 on days 1, 8, and 15 of
every 28-day cycle, up to a maximum of six cycles. Anti-
emetic therapy consisted of intravenous ondansetron 4 mg. In
the DOC arm, oral dexamethasone 8 mg was given 12 hours
before, 1 hour before, and 12 hours after each dose of
chemotherapy. Each new cycle of chemotherapy would only
commence if there was a minimum neutrophil count of 1.5 
109/liter and thrombocyte count of 100 109/liter. A delay of
up to 2 weeks for the blood counts to recover was allowed.
For days 8 and 15, the dose of chemotherapy would be
reduced by 25% if the neutrophil count was 1 to less than
1.5  109/liter and/or the thrombocyte count was 75 to less
than 100  109/liter and omitted if the blood counts fell
below those levels.
QoL Assessment
The European Organization for Research and Treat-
ment of Cancer (EORTC) Quality of Life-Cancer Question-
naire (version 3.0) (QLQ-C30) and the QLQ Lung Cancer–
Specific Module (EORTC QLQ-LC13) were used. Approved
Chinese and Malay translations were available for patients
who did not understand English. Assessment was done at
baseline and just before each of cycles 2 to 6 of chemother-
apy. The patient was required to answer the questionnaires
him- or herself if he or she were able to read and understand.
Otherwise, a named person (patient’s relative or our research
assistant) was allowed to read out the questions as written, in
a language the patient understood, and record the response to
each question without prejudicing the answer.
Toxicity and Response Evaluation
Toxicity assessments were done after every cycle of
treatment by direct questioning and physical examination. All
toxicities were documented according to the National Cancer
Institute Common Toxicity Criteria. Response to treatment
was assessed after every two cycles of treatment according to
World Health Organization criteria (the trial protocol was
written in year 2000). Confirmation of response was required.
Statistical Analysis
As this was a randomized phase II study, the objective
was not to carry out formal comparisons between the arms,
but rather to determine whether any (and, if so, which one) of
the treatment arms was sufficiently promising to warrant
further testing in a phase III trial. Hence, hypothesis tests
were not carried out to compare the groups.
QoL data were analyzed based on the guidelines for
assessing QoL in EORTC clinical trials and taking into
consideration the approaches recommended by Fairclough.14
No imputation for missing values was carried out. Scores
were rescaled to 0 to 100, with higher scores representing
better QoL. The global health score on the QLQ-C30 ques-
tionnaire, as well as the cough and dyspnea symptom scales
of the QLQ-LC13 were the main outcomes of interest. The
variation in mean QoL scores across the cycles was plotted.
For progression-free and overall survival, survival
curves were obtained using the method of Kaplan-Meier.
RESULTS
Patient Characteristics
The trial opened in November 2000 and was closed to
accrual in January 2005. One hundred thirty-five patients
were recruited. One patient was found ineligible because of
untreated brain metastasis and was excluded from analysis.
Of the 134 eligible patients, 43 received GEM, 45 received
VIN, and 46 received DOC. Patient characteristics are listed
in Table 1. The treatment arms were well balanced with
respect to all characteristics. Eighty-eight patients (66%)
were aged 70 and older. Twenty-seven patients (20%) had a
PS of ECOG 2 and 63 patients (47%) had a PS of ECOG of
3. In the group of patients younger than 70 years old, 76%
had a PS of ECOG 3, whereas for patients 70 and older, 32%
had a PS of ECOG 3.
Treatment Received
The median number of chemotherapy cycles received
was two for all treatment arms. Thirty-five percent of patients
in the GEM arm, 42% in the VIN arm, and 35% in the DOC
arm received four or more cycles of treatment. The median
relative dose intensity was 0.99 for GEM (range, 0.63–1.11),
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0.92 for VIN (range, 0.5–1.07), 0.99 for DOC (range, 0.43–
1.07). The percentage of day 8 and day 15 doses omitted or
dose-reduced were 10% or less except for the VIN arm, in
which 18.1% of the day 15 doses required dose reduction and
27.5% were omitted (Table 2).
Patients with a PS of ECOG 0-1 received a median of
three cycles of treatment, whereas those with PS of ECOG 2
and ECOG 3 received a median of two cycles, with a median
relative dose intensity of 0.97 (range, 0.62–1.11), 0.99 (range,
0.59–1.04), 0.97 (range, 0.43–1.1), respectively. Patients
younger than 70 received a median of two cycles of treat-
ment, whereas those aged 70 and older received a median of
three cycles of treatment. The median relative dose intensity
was 0.99 (range, 0.59–1.1) and 0.96 (range, 0.43–1.11),
respectively.
Response
Data on efficacy are summarized in Table 3. The
overall response rate (complete response and partial re-
sponse) was 16% for GEM, 20% for VIN, and 22% for DOC.
Unconfirmed responses were documented as not assessable.
Although DOC appeared to be the most promising, there was
no significant difference between the three arms.
The overall response rate for patients with PS of ECOG
0-1, ECOG 2, and ECOG 3 was 20%, 19%, and 19%,
respectively. For patients younger than 70, it was 15% and for
patients 70 and older, it was 22%.
Toxicity
Nausea and vomiting were uncommon. Grade 3/4 fa-
tigue was experienced in 12% of patients receiving GEM,
22% of patients receiving VIN, and 20% of patients receiving
DOC (Table 4). The rate of grade 3/4 neutropenia appeared
significantly higher in the VIN arm (35% versus 7% in both
GEM and DOC arms). There were three episodes of neutro-
penic fever, all occurring in the VIN arm. Pronounced alo-
pecia (grade 2) was more common in the DOC arm.
In addition to treatment-related toxicities, one patient
who received DOC developed deep vein thrombosis of the
left lower limb and one patient who received GEM devel-
oped pulmonary embolism. There were 35 admissions for
fever, of which 23 were attributed to pneumonia. There
were 63 admissions for management of symptoms and
progression of cancer.
Of the 126 deaths reported, 114 were from progression
of cancer. Seven patients died of pneumonia, one died of
pulmonary embolism, and one patient committed suicide. The
cause of death was not known in three patients.
QoL Analysis
Baseline QoL assessment was obtained in 94% of
patients, and the subsequent attrition was consistent with the
decreasing number of patients who were alive and who were
able to continue with chemotherapy.
The variation in QLQ-C30 global health scores over the
treatment period is shown in Figure 1. Mean values and
associated SEs are plotted. The number of patients with
available QoL data is listed for each treatment cycle under the
horizontal axis. The results suggest that the QoL of patients in
all three arms improved over the treatment period. In partic-
ular, specific symptom scores suggested that there were
improvements in the severity of cough (Figure 2) and hemop-
tysis over the treatment period.
On comparing patients with different PS, the results
suggested that the change in QoL with respect to breathless-
ness was most marked in patients with a PS of ECOG 3 in
contrast to patients with a PS of ECOG 0-1 and ECOG 2
(Figure 3).
TABLE 2. Percentage of Doses Modified/Omitted
Day 8 Treatment Day 15 Treatment
75% Dose Omitted 75% Dose Omitted
GEM 5% 6.7% 5% 6.7%
VIN 1.4% 2.8% 18.1% 27.5%
DOC 0% 2.9% 0.7% 10%
GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel.








Gender (male/female) 27/16 32/13 31/15
Age, y, median (range) 72 (42–90) 73 (47–94) 72 (45–79)
Smoking status (current/ex/non) 11/18/14 16/18/11 12/21/13
ECOG performance
0 0 1 1
1 14 14 14
2 8 7 12
3 21 23 19
Histology
Adenocarcinoma 25 20 23
Squamous cell carcinoma 12 7 13
Large cell carcinoma 2 5 2
Others 1 6 4
Not specified 3 7 4
Disease stage (III A/III B/IV) 0/9/34 1/9/35 0/12/34
GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel; ECOG, Eastern Coopera-
tive Oncology Group.







Tumor response (no. of patients)
Complete response 0 0 0
Partial response 7 9 10
Stable disease 9 14 12
Progressive disease 11 10 12
Not assessable* 16 12 12
Overall response rate 16% 20% 22%
*Thirty-three patients could not complete two cycles of chemotherapy; two patients
had unconfirmed response; five patients did not receive any treatment. GEM, gemcit-
abine; VIN, vinorelbine; DOC, docetaxel.
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Performance Status
A high attrition rate was expected from this cohort of
patients and hence the PS of patients at the start of cycle 2
was deemed most reflective of the effect of treatment. Twen-
ty-seven percent of patients had improvement in ECOG score
by 1; the ECOG score remained the same in 58% and
deteriorated in 15%.
Survival
The median progression-free survival times were 3.42,
2.99, and 2.78 months, respectively, for the GEM, VIN, and
DOC arms (Figure 4). At the time of analysis, 41 patients in
the GEM arm, 41 patients in the VIN arm, and 44 patients in
the DOC arm have died. The median overall survival time
was 5.16 months for GEM, 6.80 months for VIN, and 5.06
months for DOC (Figure 5).
Subset analysis of survival functions by PS showed me-
dian overall survival to be 7.62, 4.99, and 3.45 months for
ECOG 0-1, ECOG 2, and ECOG 3 patients, respectively. Me-
dian progression-free survival was 3.83, 2.96, and 1.84 months
for ECOG 0-1, ECOG 2, and ECOG 3 patients, respectively.
DISCUSSION
Just as we have learned not to neglect and exclude
patients with advanced stage IIIB/IV NSCLC from treat-
ment, there has been a growing desire in the oncology
TABLE 4. Toxicities
GEM (n  43) VIN (n  45) DOC (n  46)
Grade 1 2 3 4 3/4 (%) 1 2 3 4 3/4 (%) 1 2 3 4 3/4 (%)
Edema 7 6 1 1 (2) 5 1 12 9 1 1 (2)
Fatigue 14 13 5 5 (12) 10 12 9 1 10 (22) 10 19 8 1 9 (20)
Alopecia 8 4 10 6 13 16
Injection site 3 4 1 3
Constipation 14 2 1 1 (2) 14 3 3 3 (7) 10 13 1 1 (2)
Nausea 5 8 8 8 1 1 (2) 9 10 4 4 (9)
Vomiting 2 5 2 3 1 1 (2) 4 5
Neuropathy 13 2 18 1 1 (2) 16 7 1 1 2 (4)
Myalgia 11 8 19 5 1 1 (2) 12 7 1 1 (2)
Hemoglobin 19 13 5 1 6 (14) 16 20 3 2 5 (11) 21 16 1 1 (2)
Whole count 6 4 7 9 9 1 10 (22) 4 7 3 3 (7)
Neutrophils 5 5 2 1 3 (7) 4 8 10 6 16 (36) 5 1 2 1 3 (7)
Platelets 4 1 1 (2) 1 1
SAP 13 4 1 1 (2) 15 2 19 1 2 2 (4)
Bilirubin 2 1 2 5
SGOT (AST) 9 9 1 12
SGPT (ALT) 6 1 7 2 8 1
GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel; SAP, serum alkaline phosphatase; SGOT (AST), serum glutamate oxaloacetate transaminase (aspartate aminaotrans-
ferase); SGPT (ALT), serum glutamate pyruvate transaminase (alanine aminotransferase).
FIGURE 1. Quality of Life-Cancer 30 Questionnaire (version
3.0) global health scores by treatment groups. QoL, quality
of life; GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel.
FIGURE 2. Quality of Life Questionnaire Lung Cancer–Spe-
cific Module scores by treatment group. QoL, quality of life;
GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel.
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community to manage poor PS and elderly patients with
more than just best supportive care. This perceived poorly
tolerant group accounts for a significant portion of NSCLC
patients. In our own series of 957 patients,15 40% were
patients 70 years or older and 21% had a PS of 2 or 3. It
is also increasingly evident that elderly patients and poor
PS patients behave differently, and studies are now tar-
geted at each specific population. However, at the time when
the study was conceived, these two groups of patients were still
treated collectively as a “special population” and often managed
as one entity.
The assumption of poor tolerance and compliance to
aggressive treatment by these patients is not unfounded.
Their clinical course is often punctuated by frequent ad-
missions, both related and unrelated to their cancer. As
seen in our study, there were 117 admissions, of which 63
were for management of cancer symptoms and disease
progression.
Treatment regimens need to be tailored such that the
patients derive benefit without compromising their QoL.
Many studies have been dedicated to evaluate the treat-
ment options in both elderly and PS 2 patients in the past
few years.16–18 Aggregate results suggested that it was
feasible to treat such patients and achieve reasonable
objective response rates. In other instances, improvement
in QoL had been demonstrated despite little effect on
survival. In a study with a large number of poor PS patients
(72% had a Karnofsky PS of 60–70) comparing a weekly
schedule of single-agent gemcitabine with best supportive
care, patients who received gemcitabine reported better
QoL and reduced disease-related symptoms. There was no
difference in overall survival.19
A weekly administration schedule for all treatment
arms was adopted for our study in an attempt to optimize
tolerability. Our results showed that the weekly treatment
regimen using GEM, VIN, or DOC was well tolerated by
the study population, with a low rate of grade 3 or 4
toxicities. Although the median number of cycles received
by the patients was less than what might be expected from
patients who were younger and had a good PS, clinically
meaningful responses were still seen, and this was shown
by the improved QoL indices. This was particularly seen in
patients with PS 3 who responded to chemotherapy, sug-
gesting that the benefit attained in terms of symptom
alleviation may actually be greatest in the group consid-
ered least likely to benefit from treatment. However, de-
spite improvement in QoL, the median overall survival and
progression-free survival remained dismal in those with a
poor PS. As such, one would expect the improvement in
QoL to be short-lived.
We were not able to show any significant advantage of
any of the treatment arms over the rest, although there was a
suggestion of higher response rate in the DOC arm. However,
FIGURE 4. Progression-free survival by treatment group.
GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel.
FIGURE 3. Quality of Life Questionnaire Lung Cancer–Spe-
cific Module question 3 scores by Eastern Cooperative On-
cology Group (ECOG) status.
FIGURE 5. Overall survival by treatment group. GEM, gem-
citabine; VIN, vinorelbine; DOC, docetaxel.
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a recently published, larger phase III trial by Kudoh et al.20
comparing 3-weekly DOC and days 1 and 8 dosing of VIN
showed significant superiority of DOC in response rate and
progression-free survival. This may in part be contributed by
the different dosing schedule of DOC.21
Although this study showed that the weekly schedule
using single-agent GEM, VIN, or DOC is feasible for poor
PS and/or elderly patients, resulting in improvement in
QoL for those who were able to continue with the treat-
ment, it by no means implies that such a regimen should be
considered the standard of care for these patients. Several
questions remain unanswered. The patients included in this
study comprised a heterogeneous group. Selected elderly
patients with a good PS may still benefit from combination
chemotherapy,9,22 although a large randomized study com-
paring VIN, GEM, and VIN plus GEM showed that the
combination treatment was more toxic and did not improve
survival.6 In a recently completed phase III study that
enrolled 400 PS 2 NSCLC patients, Langer et al.23 showed
that combination chemotherapy using carboplatin together
with paclitaxel or paclitaxel poliglumex was feasible and
resulted in a median survival of 7.9 months. Another study
that also recruited patients with PS 2 compared three single
agents: paclitaxel poliglumex, GEM, and VIN.24 This
study is completed, and results are awaited. The jury is still
out as to whether combination treatment or single-agent, if
any, is more appropriate for PS 2 patients. In the only
reported study that included the equivalence of PS 3
patients, Baka et al.25 compared two schedules of GEM:
1000 mg/m2 on days 1, 8, and 15 every 28 days or 1500
mg/m2 days 1 and 8 every 21 days. Forty-three percent of
patients in this study had a Karnofsky PS of 60. Objec-
tive response rate was only 7.6% and median survival was
3 months. However, there was significant improvement
in PS after two cycles of chemotherapy with a trend
favoring the 28-day schedule. It is probable that elderly
patients, patients with PS 2, and patients with PS 3 tolerate and
benefit from treatment differently, and similar treatment regi-
mens may not be appropriate across these patient groups. In-
deed, our own study showed that PS was more predictive of
outcome than age alone. In our study, the median survival was
2.73 months for patients aged younger than 70 and 7.49 months
for those aged 70 and older. This was most probably due to the
overrepresentation of PS 3 patients in the younger than 70 cohort
(76% versus 32%).
Improvement in survival outcome had traditionally
been the gold standard for any experimental therapeutics to
be accepted into mainstream therapy, and few studies have
been done to address this for poor PS patients. Although we
acknowledge that improvement in QoL is an important end-
point in palliative treatment, it is arguable whether this index
alone is sufficient to issue the stamp of approval for a costly
and potentially toxic treatment for all such patients. The
durability of improved QoL is probably a more robust eval-
uator. Socioeconomic issues and patient and caregiver atti-
tudes toward treatment and their expectation on outcome are
also important factors for consideration. Future studies
should attempt to address these issues.
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